Featured Stories

Pipeline

Pipeline

Daiichi Sankyo markets pharmaceuticals for hypertension, hyperlipidemia, and bacterial infections. The company is engaged in the development of treatments for thrombotic disorders and focused on the discovery of novel oncology and cardiovascular-metabolic therapies. read more...

Career

Career

Looking for a job at Daiichi Sankyo Europe? We offer opportunities for your personal career in an international environment. read more...

Featured News

Date Description  
08-25-2014Company ESC Congress 2014: Make Your Heart Feel Good! PDF
05-17-2014Company World Hypertension Day 2014 PDF
04-06-2014Company Combination of Sun Pharma and Ranbaxy in India PDF
03-31-2014Research Daiichi Sankyo Initiates Phase 3 ENSURE-AF Study, Investigating Once-Daily Edoxaban in Patients with Atrial Fibrillation Undergoing Cardioversion PDF
01-09-2014Company Daiichi Sankyo Submits SAVAYSATM (edoxaban) Tablets New Drug Application to the U.S. FDA for Once-Daily Use for Stroke Risk Reduction in Atrial Fibrillation and for the Treatment and Prevention of Recurrence of Venous Thromboembolism PDF
01-07-2014Company Daiichi Sankyo Submits Edoxaban Marketing Authorization Application to the EMA for Once-Daily Use for Stroke Prevention in Atrial Fibrillation and for the Treatment and Prevention of Recurrence of Venous Thromboembolism PDF
12-19-2013Company Launch of LIXIANA® in Japan PDF
07-29-2013Research Daiichi Sankyo expands collaborative drug discovery program to Germany, Switzerland, and Austria
06-27-2013Company Data Reveals Changes in Management of Patients Living with Atrial Fibrillation in Europe PDF
05-21-2013Company Daiichi Sankyo increases sales in FY 2012
04-25-2013Research Perosphere and Daiichi Sankyo Enter into a Clinical Trial Agreement to Evaluate the Efficacy and Safety of PER977 to Reverse the Anticoagulant Activity of the Investigational, Oral, Once-Daily Factor Xa Inhibitor Edoxaban PDF
03-22-2013Company Daiichi Sankyo announces new five-year business plan
03-14-2013Company Daiichi Sankyo Recognized Among the 2013 Rebrand 100 Global Awards Winners PDF
02-27-2013Company Ranbaxy surpasses 2012 guidance
01-31-2013Company Daiichi Sankyo reports higher sales and profit
11-13-2012Company Daiichi Sankyo posted financial results for first six month of financial year 2012
10-25-2012Research Daiichi Sankyo Completes Enrolment in Hokusai – VTE, investigating once-daily Edoxaban in the Largest Single Phase 3 Study for the Treatment and Prevention of Recurrence of VTE PDF
10-24-2012Research ArQule and Daiichi Sankyo announce discontinuation of Phase 3 MARQUEE clinical Trial in Non-Small Cell Lung Cancer
07-09-2012Company Jan Van Ruymbeke to become new CEO of Daiichi Sankyo Europe PDF
05-11-2012Company Daiichi Sankyo posted results for financial year 2011 PDF
03-06-2012Company Ranbaxy Launches Atorvastatin in Germany PDF
11-07-2011Company Daiichi Sankyo Europe boosts net sales PDF
10-04-2011Company Ranbaxy to extend Daiichi Sankyo product reach to pharmacists across Italy PDF
06-07-2011Company European survey highlights the risk to patients caused by inconsistency in hypertension management PDF
04-22-2011Company First market approval in Japan for LIXIANA(®) (Edoxaban) PDF
04-18-2011Research Global phase III trial with selective c-MET inhibitor tivantinib (ARQ 197) starts enrolling patients PDF
04-18-2011Company Daiichi Sankyo offers assistance to victims of the Great East Japan earthquake PDF
03-14-2011Company Daiichi Sankyo contributes to relief efforts for Japan earthquake victims PDF
02-28-2011Company Plexxikon Inc. To Join Daiichi Sankyo Group PDF
01-12-2011Research Daiichi Sankyo and ArQule enroll first non-small cell lung cancer patient into global phaseIII trial PDF
12-02-2010Company Daiichi Sankyo completes enrollment of the Edoxaban global phase III engage AF-TIMI 48 study PDF
10-29-2010Company Daiichi Sankyo raised its profit forecast by almost 18% PDF
10-29-2010Company AstraZeneca and Daiichi Sankyo announce Co-promotion agreement for Esomeprazole (Nexium) PDF
10-12-2010Research ArQule and Daiichi Sankyo expand drug discovery collaboration in oncology PDF
06-22-2010Company Daiichi Sankyo remains on growth course in Europe PDF
04-06-2010Company Daiichi Sankyo submits first new drug application for oral factor Xa inhibitor edoxaban PDF
03-08-2010Company Daiichi Sankyo launches guide on International Women's Day PDF
02-26-2010Research HOKUSAI VTE - largest single phase III trial for the treatment and prevention of recurrent VTE start PDF
10-20-2009Company Improvement through Movement - new educational programme launched PDF
10-20-2009Research MorphoSys and DAIICHI SANKYO Forge Alliance to Develop Novel Antibody Therapies PDF
09-06-2009Company Substantial increase in sales and employee numbers at DAIICHI SANKYO EUROPE in 2008 PDF
09-01-2009Company Ranbaxy introducing osteoporosis drug EVISTA® into the Romanian market PDF
09-01-2009Research Edoxaban - next generation oral anticoagulant under investigation to help prevent stroke in patients PDF
07-10-2009Company DAIICHI SANKYO and Lilly receive U.S. FDA approval for EFFIENT® PDF
03-11-2009Research DAIICHI SANKYO awarded the "Best Cardiovascular Pipeline" PDF
03-08-2009Company Time for change - International Womens Day PDF
03-02-2009Company DAIICHI SANKYO takes over cardiovascular sales force from Merck Serono in Italy PDF
02-23-2009Company European Commission Approves EFIENT® (prasugrel) PDF
02-02-2009Company DAIICHI SANKYO appoints Managing Director for Ireland PDF
01-22-2009Company Blood pressure goal missed by two thirds of patients PDF